Cargando…
Improvement of Severe Fatigue Following Nuclease Therapy in Patients With Primary Sjögren’s Syndrome: A Randomized Clinical Trial
OBJECTIVE: To assess the safety and efficacy of RSLV‐132, an RNase Fc fusion protein, in a phase II randomized, double‐blind, placebo‐controlled clinical trial in patients with primary Sjögren’s syndrome (SS). METHODS: Thirty patients with primary SS were randomized to receive treatment with RSLV‐13...
Autores principales: | Posada, James, Valadkhan, Saba, Burge, Daniel, Davies, Kristen, Tarn, Jessica, Casement, John, Jobling, Kerry, Gallagher, Peter, Wilson, Douglas, Barone, Francesca, Fisher, Benjamin A., Ng, Wan‐Fai |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7839752/ https://www.ncbi.nlm.nih.gov/pubmed/32798283 http://dx.doi.org/10.1002/art.41489 |
Ejemplares similares
-
Pain and depression are associated with both physical and mental fatigue independently of comorbidities and medications in primary Sjögren’s syndrome
por: Hackett, Kate L, et al.
Publicado: (2019) -
Sjögren’s and non-Sjögren’s sicca share a similar symptom burden but with a distinct symptom-associated proteomic signature
por: Pucino, Valentina, et al.
Publicado: (2022) -
Genetic variants at the RTP4/MASP1 locus are associated with fatigue in Scandinavian patients with primary Sjögren’s syndrome
por: Norheim, Katrine Brække, et al.
Publicado: (2021) -
Phosphatidylinositol 3-kinase delta pathway: a novel therapeutic target for Sjögren’s syndrome
por: Nayar, Saba, et al.
Publicado: (2019) -
Variability of Primary Sjögren's Syndrome Is Driven by Interferon‐α and Interferon‐α Blood Levels Are Associated With the Class II HLA–DQ Locus
por: Trutschel, Diana, et al.
Publicado: (2022)